Participated · Series B · Apr 2026

Founded in 2019, Xoople has developed a tech stack around government-collected spacecraft data and integrations with cloud providers, aiming to operate its own satellite constellation and optical sensors. The company has focused on data quality and embedding its data distribution into enterprise platforms such as Microsoft and Esri. Xoople recently signed a deal with L3Harris Technologies to begin building sensors for its spacecraft and says those systems will collect optical data. The startup faces established competitors that already operate satellites, including Vantor, Planet, BlackSky, and Airbus. Financially, Xoople has raised $225 million to date, including a $130 million Series B led by Nazca Capital. Management has said it continues to raise capital to fund full development and declined to disclose a valuation, noting they are “in unicorn territory.”

Led · Debt Financing · Mar 2026

Eranovum operates and deploys electric-vehicle charging infrastructure and also produces renewable energy as an independent power producer. The company is executing a plan to deploy roughly 1,000 charging points across Spain, France and Belgium, supported by the recent €16 million financing package. In Spain alone the firm will build 590 new charging points in 113 urban locations across multiple autonomous communities, with works starting this year and roll-out continuing through the end of 2028. Eranovum emphasizes integration between charging infrastructure and renewable generation and targets high-rotation urban sites including municipal tenders, supermarkets, shopping centers and urban parking. The recent financings provide long-term institutional capital and project finance structures intended to align funding with the profile of its energy infrastructure assets and to accelerate the group's European growth plans.

Participated · Equity · Oct 2025

Feedzai delivers an end-to-end financial crime prevention platform that replaces the patchwork of point solutions typically used by banks with a single, AI-driven suite. Its multi-product offering spans bank account openings, credit-card and payment transaction monitoring, anti-money-laundering controls, and more. Recent additions such as Feedzai Orchestration and Feedzai IQ arm risk teams with faster, more precise decisioning capabilities, while the TRUST Framework embeds responsible AI principles throughout the stack. The company currently safeguards more than $70 billion in annualized payment volume, has prevented over $2 billion in fraud losses, and saved 20 million analyst hours to date. Feedzai’s platform is increasingly becoming core infrastructure as financial institutions migrate from legacy tools to AI-native systems. With fresh capital and a valuation exceeding $2 billion, management plans to intensify product innovation so every present and future payment method can be adopted safely.

Led · Equity · Sep 2025

Founded in 2013, Highlight Therapeutics is a Spanish biotech focused on innovating immunotherapies for cancer, particularly skin tumours. Its lead investigational compound, BO-112, is a double-stranded RNA therapy that mimics viral infection to activate the immune system against tumour cells. BO-112 is currently in a Phase 2b clinical trial for basal cell carcinoma and has already shown activity in aggressive melanoma, with plans to expand into additional tumour types. The company collaborates closely with the Spanish National Cancer Research Center (CNIO), from which the BO-112 programme originated. Fresh funding will allow Highlight to accelerate clinical development, strengthen its team, and broaden its pipeline. Recent executive hires, including Chief Business Officer Abel Riera, signal a push toward business development and future partnerships. The firm positions itself as a leader in accessible, transformative cancer therapies backed by strong scientific foundations.

Led · Seed · Jun 2025

PFx Biotech builds a precision fermentation platform to produce bioidentical human milk proteins such as lactoferrin for use in advanced nutrition products. Its proteins are non-GMO, dairy- and animal-free, highly bioactive, easily digestible and aimed to be allergy-free and suitable across life stages including infant, elderly and sports nutrition. The company plans to scale up production to pre-industrial levels, establish bespoke labs, and grow its team. PFx is actively exploring strategic collaborations across R&D, scale-up, and go-to-market opportunities. Financially, it closed a €2.5 million Seed round and simultaneously secured a €2.5 million EIC Accelerator grant to support scale-up. The team brings experience in dairy proteins, fermentation, molecular biology, scale-up and open innovation, with a sustainability focus.